Even individuals in the pharmaceutical sector, who are wealthy, weep. After the excitement of the pandemic passes, Pfizer must cope with the over 50% decline in its share price, which results in a loss of 140 billion dollars in market value.
According to Forbes magazine, this is the lowest level since before the epidemic. Additionally, the publication La Verità reports that American society is struggling following the significant agreements reached with Covid, with zero growth predicted by 2024.
With the help of the German company BioNTech, the Big Pharma behemoth generated over $100 billion in sales in 2022. Pfizer's CEO, Albert Bourla, stated in February 2022 that the company's external perception has drastically altered as a result of Pfizer's leadership in the battle against Covid-19.
We are running, but in the wrong direction, after 24 months. The pharmaceutical company revealed on December 13 that its yearly revenue and profitability would not meet projections. As a result, its shares dropped 7% in morning trading to $26.50, one of their lowest points since January 2009.
A $500 million decrease was also revealed by the corporation. Pfizer had to cope with a lower turnover for the Comirnaty vaccination and the antiviral tablet in October, following a 57 billion dollar year for anti-Covid goods. The business projects a 90% decline in sales from Covid products in comparison to 2022.
To put it briefly, there could be those at the Manhattan offices who are looking for a fresh pandemic windfall. Speaking to analysts, Albert Bourla predicted that the market will see some Covid 19 weariness and anti-vaccine sentiment. However, he said that the virus is unpredictable and that he believes the vaccination and the antiviral drug Paxlovid will still be important items in 2024.